Patenting medical treatments in the US and Europe – a guide for practitioners

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings
Patents

Patenting medical treatments in the US and Europe – a guide for practitioners

Paul Calvo, 
Eldora Ellison, Sara Keeble, Anja Fux, Eva Ehlich
October 21, 2024
Flags of the USA and the European Union. American Flag and EU Flag. Flag inside stars. World flag concept

Lawyers at Maiwald and Sterne Kessler analyse how patents with claims directed to medical treatments are handled in the US and in Europe

Unlock this content.

The content you are trying to view is exclusive to our subscribers.

To unlock this content:

Take a Free Trial or Login

Topics

FeaturesEuropean Patent ConventionUnited StatesPatentsMaiwaldSterne Kessler
Calvo Paul square-modified bw.jpg
Paul Calvo
Director Sterne Kessler
Ellison Eldora square-modifiedbw.jpg
Eldora Ellison
Director Sterne Kessler
Keeble Sara square-modifiedbw.jpg
Sara Keeble
Student Associate Sterne Kessler
Anja Fux.jpg
Anja Fux
Associate Maiwald
Contact
Eva Ehlich.jpg
Eva Ehlich
Partner Maiwald
Contact
more from across site and ros bottom lb

More from across our site

Patents
Rolls 2k-comp.jpg
Delayed IP judgments under scrutiny in the UK
Courts are encouraged to deliver judgments within three months of a trial, but that deadline has been missed in several recent cases
James Nurton, October 21, 2024
August 21, 2019 San Francisco / CA / USA - Close up of Salesforce logo displayed on one of their towers in downtown San Francisco
KWM litigator: economical approach helped reverse ‘exceptional’ finding
Michael DeVincenzo explains how he and his team convinced the Federal Circuit to find in favour of his client in a patent case against Salesforce
Rani Mehta, October 18, 2024
Patents
TreasureTrove.jpg
Mandatory funding disclosures could be a ‘treasure trove’ for litigators
Funders and a litigator explain how litigation funding disclosure requirements could affect their business
Rani Mehta, October 18, 2024
Patents
Ericsson 2.jpg
This week on MIP: Powell Gilbert co-founder joins US firm | Ericsson's UPC blow
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Max Walters, October 18, 2024
Patents
Inspect or review document, report or legal audit, quality assur
How law firms manage USPTO director review requests
Discussions about whether to seek director reviews can come up frequently with clients, even though actual grant rates are rare
Rani Mehta, October 17, 2024
Patents
MIP Podcast newsletter header banner sample-2000.jpg
The IP Lounge: Why PE and IP attract, rankings latest
In the latest episode, we discuss why IP firms might be attractive to PE investors and bring you the latest news on submissions for next year’s IP STARS rankings
Max Walters, October 17, 2024
Patents
Goldmine.jpg
Weekly take: Why ‘goldmine’ IP firms should consider private funding
Back-to-back PE deals for IP firms in recent years show that IP firms are sitting on goldmines, so traditional partnerships should be open to change
Sukanya Sarkar, October 17, 2024
Patents
Location Boston city in Massachusetts, map with red push pin pointing close-up, USA, United States of America
100-days-in: new ArentFox Schiff partner eyes further Boston growth
Joseph Maraia, whose team left Burns & Levinson shortly before it closed, says ArentFox Schiff is looking at the right opportunities
Rani Mehta, October 17, 2024
Trademarks
Turkey.jpg
Seven-year itch: Turkish firms slam lack of guidance over TM law
Practitioners reveal how changes to non-use cancellations, first outlined in 2017 but yet to be formalised, are affecting their strategies
Sukanya Sarkar, October 16, 2024
Sponsored content
research-7116736.jpg
CNIPA’s new tweak over inventiveness assessments of co-solvent compound crystals
Wu Xiaohui of Wanhuida Intellectual Property explains why a recent decision on inventiveness assessments of co-solvent compound crystals heralds a significant shift in focus by the CNIPA, with implications for pharmaceutical patent strategies
Wu Xiaohui, October 15, 2024
Gift this article